Dose Adjustment Patterns in the Open-Label Extension Arms of Three Phase 3 Trials of Certolizumab Pegol in Psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT

Main Article Content

A Blauvelt
AB Gottlieb
F Fierens
F Brock
S Wiegratz
H Sofen

Keywords

Psoriasis, Biologic, Tumor Necrosis Factor α, TNF-α, Certolizumab Pegol

Abstract

Abstract not available.

References

1. R. et al. J Invest Dermatol 2013;133:377–85

2. Gottlieb AB. et al. JAAD 2018;79:302–14.e6

3. Lebwohl M. et al. JAAD 2018;79:266–76.

Most read articles by the same author(s)

1 2 3 > >>